Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03640052 · ClinicalTrials.gov registry record · Phase 1
Pharmacological Activation of HMN for OSA
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03640052: Completed Phase 1 study, sponsored by Brigham and Women's Hospital.
NCT03640052 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03640052, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201L, LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA severity during sleep.
Primary Outcome
Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive \>50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.
Interventions
- DRUG Placebo oral capsule
- DRUG LTM1201L
- DRUG LTM1201LN
- DRUG LTM1201LB
- DRUG LTM1201LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
What the finished NCT03640052 record still lists
NCT03640052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo oral capsule is the first listed.
NCT03640052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03640052 about?
NCT03640052 is a clinical study titled "Pharmacological Activation of HMN for OSA". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In th...
What is the current status of trial NCT03640052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-10-30. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03640052?
The interventions under investigation include: Placebo oral capsule (DRUG), LTM1201L (DRUG), LTM1201LN (DRUG), LTM1201LB (DRUG), LTM1201LD (DRUG).
Who is sponsoring clinical trial NCT03640052?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03640052's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI